PapersFlow Research Brief
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Research Guide
What is Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis?
Interstitial lung diseases are a group of disorders characterized by inflammation and scarring in the lung interstitium, with idiopathic pulmonary fibrosis (IPF) being a progressive, fatal form marked by excessive extracellular matrix deposition leading to lung stiffening and respiratory failure.
The field encompasses 79,114 published works on the diagnosis, management, and pathogenesis of IPF and related interstitial lung diseases. Key areas include evidence-based guidelines, cellular mechanisms like myofibroblast activation and epithelial-mesenchymal transition, and treatments such as pirfenidone and nintedanib. Growth data over the past five years is not available.
Topic Hierarchy
Research Sub-Topics
Idiopathic Pulmonary Fibrosis Diagnosis
This sub-topic covers multidisciplinary diagnostic approaches for IPF, including high-resolution CT patterns, histopathological criteria, and guideline updates. Researchers develop and validate non-invasive biomarkers and diagnostic algorithms.
Pirfenidone in Idiopathic Pulmonary Fibrosis
This sub-topic examines clinical trials, efficacy, safety profiles, and real-world outcomes of pirfenidone in slowing IPF progression. Studies explore biomarkers of response and combination therapies.
Nintedanib for Pulmonary Fibrosis
This sub-topic focuses on nintedanib's mechanism, phase III trials, and applications in IPF and progressive fibrosing interstitial lung diseases. Researchers investigate long-term safety and comparative effectiveness.
Myofibroblast Differentiation in Lung Fibrosis
This sub-topic studies the origin, activation, and persistence of myofibroblasts in lung fibrosis pathogenesis. Research includes signaling pathways, senescence, and therapeutic targeting of myofibroblast plasticity.
TGF-β Signaling in Pulmonary Fibrosis
This sub-topic explores TGF-β pathways in epithelial injury, fibroblast activation, and fibrosis resolution in IPF. Researchers investigate downstream mediators and selective inhibitors.
Why It Matters
Guidelines like "An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management" (Raghu et al., 2011) standardize IPF diagnosis and management, aiding clinicians in high-risk cases where early intervention slows progression. Clinical trials demonstrate nintedanib reduces forced vital capacity (FVC) decline in IPF patients, with discontinuation due to diarrhea in less than 5% (Richeldi et al., 2014, "Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis"). Similarly, pirfenidone reduces disease progression, improving lung function, exercise tolerance, and progression-free survival while showing fewer deaths compared to placebo (King et al., 2014, "A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis"). These antifibrotic therapies address unmet needs in pulmonary medicine, impacting patient survival in interstitial lung diseases.
Reading Guide
Where to Start
"An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management" (Raghu et al., 2011) is the starting point, as it provides foundational evidence-based recommendations on IPF diagnosis and management for clinical practice.
Key Papers Explained
Raghu et al. (2011, "An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management") establishes core diagnostic and management guidelines, updated by Travis et al. (2013, "An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias") with refined IIP classification. Richeldi et al. (2014, "Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis") and King et al. (2014, "A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis") build on these by demonstrating antifibrotic drug efficacy in slowing FVC decline. Aran et al. (2019, "Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage") adds cellular insights into pathogenesis, linking to Wynn (2007, "Cellular and molecular mechanisms of fibrosis").
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent guidelines refine IPF diagnosis with multidisciplinary input (Raghu et al., 2018, "Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline"). Single-cell sequencing highlights profibrotic macrophages (Aran et al., 2019), pointing to targeted therapies. No preprints or news from the last 12 months indicate steady progress in cellular mechanisms and classifications.
Papers at a Glance
Frequently Asked Questions
What are the evidence-based guidelines for IPF diagnosis and management?
The "An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management" (Raghu et al., 2011) provides international recommendations developed by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association. It covers diagnostic criteria and treatment strategies for IPF. These guidelines emphasize multidisciplinary approaches involving clinical, radiological, and histopathological evaluation.
How does nintedanib treat idiopathic pulmonary fibrosis?
Nintedanib slows IPF progression by reducing the annual decline in forced vital capacity (FVC) compared to placebo (Richeldi et al., 2014, "Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis"). It is associated with diarrhea, leading to discontinuation in less than 5% of patients. This tyrosine kinase inhibitor targets fibrotic pathways in lung tissue.
What role do transitional profibrotic macrophages play in lung fibrosis?
Reference-based analysis of lung single-cell sequencing identifies a transitional profibrotic macrophage population in IPF (Aran et al., 2019, "Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage"). These cells contribute to fibrosis pathogenesis through specific molecular signatures. They represent a key cellular mechanism in disease progression.
What is the current classification of idiopathic interstitial pneumonias?
The "An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias" (Travis et al., 2013) updates the 2002 classification, incorporating advances in clinical, radiologic, and pathologic features. It aids precise diagnosis of IPF and related disorders. The update highlights areas for future research.
How is pirfenidone effective in IPF patients?
Pirfenidone reduces IPF progression, as shown by improved lung function, exercise tolerance, and progression-free survival versus placebo (King et al., 2014, "A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis"). It has an acceptable side-effect profile with fewer deaths observed. This phase 3 trial supports its use in management.
What are the cellular mechanisms of fibrosis in IPF?
Fibrosis involves excess extracellular matrix deposition, including collagen, from chronic inflammation (Wynn, 2007, "Cellular and molecular mechanisms of fibrosis"). Persistent stimuli lead to myofibroblast activation and tissue scarring. These processes underlie IPF pathogenesis.
Open Research Questions
- ? What specific molecular signatures define the transitional profibrotic macrophage and its role in IPF progression?
- ? How do epithelial-mesenchymal transition pathways interact with TGF-β signaling in human lung fibrosis?
- ? Which patient subgroups benefit most from combined nintedanib and pirfenidone therapy in slowing FVC decline?
- ? What histopathological features distinguish IPF from other idiopathic interstitial pneumonias in early disease stages?
- ? How do myofibroblast persistence and bronchoalveolar lavage findings predict IPF outcomes?
Recent Trends
The field maintains 79,114 works with no specified five-year growth rate.
High-citation guidelines persist, including the 2018 update "Diagnosis of Idiopathic Pulmonary Fibrosis.
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline" (Raghu et al., 3848 citations).
Single-cell analysis advanced with Aran et al. (2019, 4902 citations), but no preprints or news coverage in the last 12 months signals ongoing focus on established guidelines and mechanisms without new disruptions.
Research Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers